Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

被引：1
|
作者：
Vaduganathan, Muthiah
Sattar, Naveed
Fitchett, David H.
Ofstad, Anne Pernille
Brueckmann, Martina
George, Jyothis T.
Verma, Subodh
Mattheus, Michaela
Wanner, Christoph
Inzucchi, Silvio E.
Zinman, Bernard
Butler, Javed
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-30-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
30-OR
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?
    Strojek, Krzysztof
    Rokicka, Dominika
    Szymborska-Kajanek, Aleksandra
    Wrobel, Marta
    CLINICAL DIABETOLOGY, 2016, 5 (03): : 107 - 110
  • [32] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [33] EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age
    Krentz, Andrew J.
    CARDIOVASCULAR ENDOCRINOLOGY, 2015, 4 (04): : 115 - 116
  • [34] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [35] Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    George, Jyothis
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wanner, Christoph
    Hauske, Sibylle
    DIABETES, 2019, 68
  • [36] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, A.
    Inzucchi, S. E.
    Testani, J.
    Ofstad, A. P.
    Fitchett, D.
    Mattheus, M.
    Verma, S.
    Zannad, F.
    Wanner, C.
    Kraus, B. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
  • [37] EMPA-REG OUTCOME: A Milestone in the Treatment of the Diabetes mellitus Type 2?
    Schneider, C. A.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 405 - 407
  • [38] Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
    Monteiro, Pedro
    Bergenstal, Richard M.
    Toural, Elvira
    Inzucchi, Silvio
    Zinman, Bernard
    Hantel, Stefan
    Kis, Sanja Giljanovic
    Kaspers, Stefan
    George, Jyothis T.
    Fitchett, David
    AGE AND AGEING, 2019, 48 (06) : 859 - 866
  • [39] The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
    Kaku, Kohei
    Wanner, Christoph
    Anker, Stefan D.
    Pocock, Stuart
    Yasui, Atsutaka
    Mattheus, Michaela
    Lund, Soren S.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 662 - 674
  • [40] Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial
    Claggett, Brian
    Lachin, John M.
    Hantel, Stefan
    Fitchett, David
    Inzucchi, Silvio E.
    Woerle, Hans J.
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 138 (15) : 1599 - 1601
12345